<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037877</url>
  </required_header>
  <id_info>
    <org_study_id>20220HUM</org_study_id>
    <nct_id>NCT05037877</nct_id>
  </id_info>
  <brief_title>An Exploratory Investigation of Dietary Supplementation and Its Effect to Support Symptoms of Menopause, Including the Frequency and Severity of Hot Flashes</brief_title>
  <official_title>An Exploratory Investigation of Dietary Supplementation and Its Effect to Support Symptoms of Menopause, Including the Frequency and Severity of Hot Flashes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HUM Nutrition, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Citruslabs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HUM Nutrition, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to understand if the test product (HUM supplement)&#xD;
      reduces the number of hot flashes in Perimenopausal women and to see if it improves mood and&#xD;
      other symptoms usually experienced with menopause. The secondary objective is to examine the&#xD;
      effect on the quality of life, safety, and tolerability of daily use of HUM menopause&#xD;
      supplementation taken daily by individuals with VMS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 2-arm randomized, double-blinded, placebo-controlled study in which&#xD;
      individuals with menopause symptoms, and in particular hot flashes and mood swings will&#xD;
      receive either daily HUM menopause supplementation or a placebo as a control for a period of&#xD;
      8 weeks.&#xD;
&#xD;
      It is hypothesized that the dietary supplement will improve subjective wellbeing in trial&#xD;
      participants by reducing symptoms of menopause.&#xD;
&#xD;
      A total of 110 participants will be recruited for the trial following screening (55 in each&#xD;
      group), with the expectation that at least 100 participants will complete the trial (50 in&#xD;
      each group). The trial will be fully remote, a technology platform will be utilized to&#xD;
      screen, enroll and capture study data of the participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a 2-arm randomized, double-blinded, placebo-controlled study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the number of hot flashes in Perimenopausal women and associated improvements of mood and other symptoms usually experienced with menopause. [Time Frame: Baseline to 8 weeks)</measure>
    <time_frame>8 week</time_frame>
    <description>Survey-based assessment (0-5 scale) of changes in hot flashes, mood, and other menopausal symptoms between baseline and 8 week study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved quality of life, safety, and tolerability of HUM menopause supplementation taken daily by individuals with VMS. [Time Frame: Baseline to 8 weeks]</measure>
    <time_frame>8 week</time_frame>
    <description>Survey-based assessment (0-5 scale) of quality of life changes parameters between baseline and 8 week study period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Hot Flashes</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HUM supplement - 1 capsule per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo supplement - 1 capsule per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HUM supplement</intervention_name>
    <description>HUM supplement - 1 capsule per day</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo supplement - 1 capsule per day</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female between 38-60 years old&#xD;
&#xD;
          -  Perimenopausal or menopausal (experienced a break-in cycle regularity during the past&#xD;
             12 months or last menstruation at least 3 months ago)&#xD;
&#xD;
          -  At least mild hot flash symptoms (as established during screening through menopause&#xD;
             rating scale question about the severity of hot flashes)&#xD;
&#xD;
          -  Non-smoker or ex-smoker for at least 6 months&#xD;
&#xD;
          -  BMI &lt;40&#xD;
&#xD;
          -  Willing to maintain the current dietary pattern, activity level, and stable body&#xD;
             weight for the duration of the study&#xD;
&#xD;
          -  Must be in good health (don't report any medical conditions asked in the screening&#xD;
             questionnaire)&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of prescription antidepressants&#xD;
&#xD;
          -  Use of hormonal therapies less than 6 months prior to screening&#xD;
&#xD;
          -  Use of dietary supplements or drugs that could affect climacteric symptoms less than 1&#xD;
             month prior to screening&#xD;
&#xD;
          -  Allergies to any test product ingredients&#xD;
&#xD;
          -  Has any of the following medical conditions:&#xD;
&#xD;
          -  Oncological conditions&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  Cardiovascular disease&#xD;
&#xD;
          -  Multiple Sclerosis&#xD;
&#xD;
          -  Any other severe chronic disease&#xD;
&#xD;
          -  Pregnant, want to become pregnant for the duration of the study, or who are&#xD;
             breastfeeding&#xD;
&#xD;
          -  Participating in an investigational health product research study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>38 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Mitschke</last_name>
    <role>Principal Investigator</role>
    <affiliation>Citruslabs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Renner, MSc</last_name>
    <phone>4242450284</phone>
    <email>hello@citruslabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Citruslabs</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Renner, MSc</last_name>
    </contact>
    <investigator>
      <last_name>Susanne Mitschke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

